Research programme: CAR-T cell therapeutics - BioAtla/F1 Oncology

Drug Profile

Research programme: CAR-T cell therapeutics - BioAtla/F1 Oncology

Alternative Names: CAB CAR-T therapy

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator BioAtla
  • Class CAR-T cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 06 Jan 2017 Early research in Solid tumours in USA (Parenteral)
  • 06 Jan 2017 F1 Oncology plans clinical trial for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top